Page 116 - 《中国药房》2025年4期
P. 116
33(5):622-627. 分析[J]. 药学实践杂志,2020,38(2):174-178.
HUANG C B,LI W P,XU R F,et al. Reevaluation of YAO N N,LIN L L,HUANG S,et al. Analysis of adverse
systematic evaluation of gemcitabine combined with cis‐ reactions in 312 cases of gemcitabine[J]. J Pharm Pract,
platin in the treatment of advanced non-small cell lung 2020,38(2):174-178.
cancer[J]. China Pharm,2022,33(5):622-627. [15] THARPE N. Adverse drug reactions in women’s health
[ 5 ] 刘卫平,谌武兵.吉西他滨联合顺铂治疗晚期NSCLC的 care[J]. J Midwifery Womens Health,2011,56(3):205-213.
临床疗效及安全性[J].临床合理用药,2024,17(12):9-12. [16] 左成淳,许青,李晓宇,等 . 替加环素肝功能异常风险的
LIU W P,SHEN W B.Clinical efficacy and safety of gem‐ 回顾性观察研究[J]. 中国医院药学杂志,2024,44(18):
citabine combined with cisplatin in the treatment of 2146-2153.
advanced NSCLC[J].Chin J Clin Rat Drug Use,2024,17 ZUO C C,XU Q,LI X Y,et al. Risk of liver function
(12):9-12. abnormalities with tigecycline:a retrospective observational
[ 6 ] BAYRAM E,TOYRAN T,PAYDAS S. Gemcitabine- study[J]. Chin J Hosp Pharm,2024,44(18):2146-2153.
associated DRESS syndrome:a case report[J]. J Oncol [17] CASTBERG I,WESTIN A A,SKOGVOLL E,et al.
Pharm Pract,2023,29(6):1480-1483. Effects of age and gender on the serum levels of clozapine,
[ 7 ] CTCAE V5.0. Common terminology criteria for adverse olanzapine,risperidone,and quetiapine[J]. Acta Psychiatr
events (CTCAE) version 5.0. 2017. [EB/OL].(2021-06- Scand,2017,136(5):455-464.
28)[2024-09-25]. https://ctep.cancer.gov/protocoldevelop‐ [18] MANTEUFFEL M,WILLIAMS S,CHEN W,et al.
ment/electronic_applications/docs/CTCAE_V5_Quick_Re- Influence of patient sex and gender on medication use,
ference_8.5x11.pdf. adherence,and prescribing alignment with guidelines[J]. J
[ 8 ] 李伯妍,郭代红,孔祥豪,等 . 972 例抗肿瘤血管生成类 Womens Health (Larchmt),2014,23(2):112-119.
药品不良反应自发报告分析[J]. 中国临床药理学杂志, [19] 羊波,孙云峰,郑造乾,等. 超说明书用药法律释读及应
2021,37(11):1441-1443,1450. 对策略分析[J]. 中国现代应用药学,2019,36(8):993-996.
LI B Y,GUO D H,KONG X H,et al. Analysis of 972 YANG B,SUN Y F,ZHENG Z Q,et al. Legal interpreta‐
spontaneous reports of adverse drug reactions induced by tion and coping strategy analysis on off-label use[J]. Chin
angiogenesis inhibitors[J]. Chin J Clin Pharmacol,2021, J Mod Appl Pharm,2019,36(8):993-996.
37(11):1441-1443,1450. [20] 国家卫生健康委办公厅 . 膀胱癌诊疗指南:2022 年版
[ 9 ] 邱爽,崔向丽,王颖 . 112 例吉西他滨不良反应分析[J]. [EB/OL].(2022-04-03)[2024-08-12]. http://www.nhc.gov.
中国新药杂志,2014,23(17):2085-2088. cn/yzygj/s2911/202204/a0e67177df1f439898683e133395-
QIU S,CUI X L,WANG Y. Analysis of 112 patients with 7c74/files/7224e506d4a24b90a9df0424888ba38a.pdf.
adverse drug reactions induced by gemcitabine[J]. Chin J Office of the National Health Commission. Guidelines for
N Drugs,2014,23(17):2085-2088. diagnosis and treatment of bladder cancer:2022 edition
[10] 马颖林,乐凯迪,闫加庆,等 . 真实世界阿帕替尼治疗乳 [EB/OL].(2022-04-03)[2024-08-12]. http://www.nhc.gov.
腺癌的不良反应及危险因素分析[J]. 中国药学杂志, cn/yzygj/s2911/202204/a0e67177df1f439898683e133395-
2022,57(4):310-314. 7c74/files/7224e506d4a24b90a9df0424888ba38a.pdf.
MA Y L,LE K D,YAN J Q ,et al.Analysis of the adverse [21] 国家卫生健康委办公厅 . 卵巢癌诊疗指南:2022 年版
reactions and risk factors of apatinib in the treatment of [EB/OL].(2022-04-03)[2024-08-12]. http://www.nhc.gov.
breast cancer in real world[J].Chin Pharmaceut J,2022,57 cn/yzygj/s2911/202204/a0e67177df1f439898683e133395-
(4):310-314. 7c74/files/0feefc11d98840898b136ac3d9a4ee20.pdf.
[11] WANG Y,HU G F,ZHANG Q Q,et al. Efficacy and Office of the National Health Commission. Guidelines for
safety of gemcitabine plus erlotinib for locally advanced diagnosis and treatment of ovarian cancer:2022 edition
or metastatic pancreatic cancer:a systematic review and [EB/OL].(2022-04-03)[2024-08-12]. http://www.nhc.gov.
meta-analysis[J].Drug Des Devel Ther,2016,10:1961-1972. cn/yzygj/s2911/202204/a0e67177df1f439898683e133395-
[12] 黄彦珊 . 2017-2020 年某院铂类药物不良反应分析[J]. 7c74/files/0feefc11d98840898b136ac3d9a4ee20.pdf.
中国处方药,2023,21(2):90-93. [22] 汪龙,朱玲娜,宋佳伟,等. 吉西他滨合理应用评价标准
HUANG Y S. Analysis of the adverse reactions of plati‐ 的建立及应用[J]. 中国新药与临床杂志,2020,39(9):
num drugs in our hospital from 2017 to 2020[J]. J China 568-574.
Prescr Drug,2023,21(2):90-93. WANG L,ZHU L N,SONG J W,et al. Establishment and
[13] 马力,时俊锋,童宁 . 紫杉醇类药物的不良反应研究[J]. application of evaluation criteria for rational use of gem‐
中国药房,2018,29(21):3014-3017. citabine[J]. Chin J N Drugs Clin Remedies,2020,39(9):
MA L,SHI J F,TONG N. Study on adverse reactions of 568-574.
taxol drugs[J]. China Pharm,2018,29(21):3014-3017. (收稿日期:2024-09-07 修回日期:2024-11-27)
[14] 姚囡囡,林莉莉,黄珊,等 . 312 例吉西他滨的不良反应 (编辑:舒安琴)
· 490 · China Pharmacy 2025 Vol. 36 No. 4 中国药房 2025年第36卷第4期